Skip to main content

STAT reports that the Trump administration faces another lawsuit from states over its changes to Medicaid, days after a federal judge said work requirements would cause “irreparable” harm. The legal challenge targets the administration’s efforts to enforce employment conditions for Medicaid eligibility.

This dispute matters for health insurers and healthcare executives who depend on Medicaid contracts, as legal uncertainty could disrupt enrolment and funding. The outcome may affect how states and providers plan for compliance and resource allocation.

States file new lawsuit to block Trump Medicaid work requirements

The Trump administration has removed two organisations responsible for arbitrating disputes under the No Surprises Act, according to STAT. The government cited the groups’ failure to meet minimum performance standards as the reason for ending their contracts.

This decision could affect the process for resolving payment disagreements between healthcare providers and insurers. Senior leaders in healthcare and insurance should monitor for potential delays or shifts in arbitration outcomes as new groups may be appointed to fill the gap.

US drops two No Surprises Act arbitrators over performance concerns

Novartis has acknowledged seven previously unknown cases of tumours in children who received its gene therapy for spinal muscular atrophy, according to STAT. The therapy, Zolgensma, is a high-profile treatment in the rare disease sector.

This disclosure is significant for pharma and biotech leaders assessing the safety profile of gene therapies. Safety incidents can affect regulatory scrutiny, patient trust and market adoption. Companies may need to review their own risk management and communication strategies as regulators assess the situation.

Novartis reports seven tumour cases in Zolgensma-treated children

PhRMA, the pharmaceutical industry’s main US trade group, spent about $59 million on search advertising in the past seven years to influence public perception of prescription drug costs, according to STAT. The report says the campaign aimed to shape how Americans view the pricing of medicines.

This level of digital advertising spend shows the value the industry places on public opinion management. For pharma and healthcare brand leaders, the story signals that digital channels are central to reputation and policy influence. CMOs may need to weigh the risks and returns of similar tactics in their own markets.

PhRMA spends $59 million on search ads to shape drug pricing debate

STAT reports that Medicare will finalise a proposal to stop hospitals and other providers from using third parties to deliver remote patient monitoring services. The rule, which faced widespread opposition, will now apply until 2029.

This decision could affect hospitals' ability to scale digital health services and may require changes to existing vendor relationships. Healthcare executives should consider reviewing current remote monitoring arrangements and prepare for operational adjustments.

Medicare to restrict third-party remote monitoring until 2029

Ultragenyx said it will lay off around 20% of its staff after halting development of two rare disease drug candidates, according to STAT. The announcement comes as the company faces setbacks in its research pipeline.

This move signals ongoing cost pressures and the challenge of managing high-risk drug development in the biotech sector. Pharma leaders may need to reassess their own project portfolios and workforce strategies in response to shifting market and research realities.

Ultragenyx cuts 20% of staff after rare disease drug setbacks

STAT reports that Congress faces a deadline to fund expiring health care programmes and confirm Health and Human Services nominees before Democrats assume control. The outcome will affect major federal programmes such as Medicaid and Medicare.

This matters for insurers and healthcare groups whose revenues and operations depend on timely federal funding. Delays or changes in programme terms could disrupt planning and cash flow. Leaders should monitor Congressional actions closely for any late amendments or funding gaps.

US Congress faces deadline to fund expiring health care programmes

Bernie Sanders could use his position in shaping the FDA funding bill to press for changes, according to STAT. The report notes that Sanders, a known critic of the pharmaceutical industry, may seek to include reforms as part of the funding process.

This development could affect regulatory requirements or pricing strategies for pharma and biotech firms. Senior executives should pay close attention to the bill’s progress, as any amendments could have direct effects on compliance, market access or costs.

Sanders may use FDA funding bill to push for pharma reforms

STAT reports that CVS Health will divide its pharmacy and insurance operations, reversing a strategy of combining the two. The decision follows ongoing attention from federal and state regulators concerned about the effects of vertical integration in healthcare.

For senior leaders in health insurance and pharma, this signals a potential change in how large firms structure their businesses. Regulatory scrutiny of integrated models may prompt other organisations to reconsider similar deals or review their compliance strategies.

CVS Health to separate pharmacy and insurance units amid regulatory pressure

STAT reports that Servier has announced a surprise setback for a drug in development for a form of muscular dystrophy with no current treatment. The drug, valued at $1.55 billion, failed its first major clinical test according to the company.

This development matters to pharma and biotech executives because it highlights the risk and uncertainty in rare disease drug pipelines. Companies with similar assets may face renewed scrutiny from investors and regulators. The news could prompt a review of clinical trial strategies and portfolio priorities across the sector.

Servier’s $1.55 billion muscular dystrophy drug fails key clinical trial